Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ITGA2 | P17301 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 3/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.39 |
| ▸ | SDCBP | O00560 | 3/20 | 0.39 |
| ▸ | SDC2 | P34741 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180430 | 1.00 | RARB (0.45) | RARBITGB3ITGA2BITGA2PLK1 | |
| SCHEMBL2176949 | 0.92 | RARB (0.44) | RARBITGB3ITGA2BITGA2PLK1 | |
| SCHEMBL2181140 | 0.92 | RARB (0.44) | RARBITGB3ITGA2BITGA2PLK1 | |
| SCHEMBL2180410 | 0.91 | ITGB3 (0.42) | ITGB3ITGA2BITGA2PLK1TRPV1 | |
| SCHEMBL2180407 | 0.91 | ITGB3 (0.42) | ITGB3ITGA2BITGA2PLK1TRPV1 | |
| SCHEMBL2179559 | 0.90 | TRPV1 (0.44) | RARBITGB3ITGA2BITGA2TRPV1 | |
| SCHEMBL2179566 | 0.90 | TRPV1 (0.44) | RARBITGB3ITGA2BITGA2TRPV1 | |
| SCHEMBL13718848 | 0.90 | PLK1 (0.41) | RARBITGB3ITGA2BITGA2PLK1 | |
| SCHEMBL2179111 | 0.90 | PLK1 (0.41) | RARBITGB3ITGA2BITGA2PLK1 | |
| SCHEMBL2178463 | 0.90 | GAA (0.44) | ITGB3ITGA2BITGA2PLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | claimed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | claimed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | claimed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | claimed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Enterprises Limited (IN) | 2012-11-15 | — | — | US | disclosed |
| EP-2519500-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | Piramal Healthcare Ltd. (IN) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080718-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289505-A1 | INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE | DGAT1, DGAT2, LCAT | RARB 2921/4885ITGB3 4621/4885ITGA2B 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.